Eledon Pharmaceuticals (ELDN) Common Equity (2013 - 2026)

Eledon Pharmaceuticals' Common Equity history runs 14 years deep, the most recent figure standing at $44.8 million for Q1 2026.

• Quarterly Common Equity fell 23.98% year-over-year to $44.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.8 million (down 23.98% YoY) and the FY2025 annual result came in at $81.1 million, up 29.85% from the prior year.
• Common Equity was $44.8 million for Q1 2026 at Eledon Pharmaceuticals, down from $81.1 million in the prior quarter.
• Across five years, Common Equity topped out at $156.3 million in Q1 2022 and bottomed at -$70.4 million in Q1 2024.
• A 5-year average of $46.8 million and a median of $44.8 million in 2026 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity plunged 303.83% — and 2024, when it jumped 228.79%.
• Eledon Pharmaceuticals' Common Equity stood at $23.8 million in 2022, then plunged by 303.83% to -$48.5 million in 2023, then soared by 228.79% to $62.4 million in 2024, then gained by 29.85% to $81.1 million in 2025, then plunged by 44.79% to $44.8 million in 2026.
• Business Quant data shows ELDN's Common Equity at $44.8 million in Q1 2026, $81.1 million in Q4 2025, and $35.4 million in Q3 2025.